DocMorris AG: Continued strong Rx growth: DocMorris raises full-year revenue forecast as part of today’s Capital Markets Day Donnerstag, 12. November 2026 - 07:02

Frauenfeld, 12 November 2026

Press release
Ad hoc announcement pursuant to Art. 53 LR

Continued strong Rx growth: DocMorris raises full-year revenue forecast as part of today’s Capital Markets Day

⋅        Full-year revenue forecast raised to around 15% (previously 12.5 to 15%)
⋅        Continued strong Rx growth in October of over 90%
⋅        TeleClinic expansion into Switzerland with high synergy potential
⋅        Capital Markets Day taking place today in Heerlen/Aachen

Sustained Rx momentum leads to higher full-year forecast
Revenue momentum in the prescription medicines (Rx) business accelerated further in October to over 90 per cent compared to the previous year. DocMorris now expects Rx growth of around 60 per cent for the full year. Against this backdrop, management is raising its forecast for external revenue growth for the full year 2026 to around 15 per cent (previously 12.5 to 15 per cent). The other annual and medium-term targets remain unchanged.

Scaling up Digital Services through the acquisition of Medi24
With the acquisition of Medi24, a leading Swiss telemedicine provider, DocMorris – through its subsidiary TeleClinic – has taken a significant step towards scaling its high-margin Digital Services business outside Germany. Thanks to rapid technology integration and operational synergies, the acquisition will make a substantial contribution to TeleClinic’s EBITDA in its first full year in 2027.

Today’s Capital Markets Day in Heerlen/Aachen
DocMorris is holding its Capital Markets Day today in Heerlen/Aachen. Members of the Executive Board and Management will provide insights into strategic development, operational progress and key value drivers in their respective areas. As part of the programme, participants will also have the opportunity to tour the state-of-the-art logistics centre in Heerlen.

All presentations are available on the website: https://ir-corporate.docmorris.com/en/investor-relations/financial-publications. Video recordings of the presentations will also be made available on the website afterwards.

Investors and analyst contact
Kelvin Jörn, Head of Investor Relations
Email: ir@docmorris.com, phone: +41 52 560 58 10

Media contact
Torben Bonnke, Director Communications
Email: media@docmorris.com, phone: +49 171 864 888 1

Agenda

DocMorris
The Swiss-based DocMorris AG is a leading company in the fields of online pharmacy, telemedicine and marketplace with strong brands in Germany and other European countries. Deliveries are mainly from the highly automated logistics centre in Heerlen, the Netherlands. TeleClinic is Germany’s largest telemedicine platform, connecting patients with more than 6,500 doctors. DocMorris operates leading marketplaces for health and personal care products in Southern Europe. With its broad range of products and services, DocMorris is pursuing its vision of becoming the leading digital health companion for everyone to manage their health in one click. Around 1,600 employees in Germany, the Netherlands, Spain, France, Portugal and Switzerland generated an external revenue of CHF 1,186 million serving over 12 million active customers in 2025. The shares of DocMorris AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker DOCM). For further information, please visit corporate.docmorris.com.

Disclaimer
This announcement contains certain forward-looking statements about DocMorris AG and its business, either explicitly or implicitly. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual results, financial position, performance or achievements of DocMorris AG to differ materially from the future results, performance or achievements expressed or implied by such forward-looking statements. DocMorris AG is making this announcement available as of today's date and undertakes no obligation to update the forward-looking statements contained herein as a result of new information, future events or for any other reason.